Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Financial analyst predicts Bausch & Lomb (BLCO) could be worth $28/share in a potential takeover, with private equity ...

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

Inc. BHC gained 14.7% in a week on reports of refinancing its debt to enable the impending sale of its eye care company, Bausch + Lomb BLCO. The industry declined 0.6% during this timeframe. The sale, ...

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...

Bausch + Lomb BLCO shares ended the last trading session ... So, make sure to keep an eye on BLCO going forward to see if this recent jump can turn into more strength down the road.

Despite these protestations, the company had posted a message on X (since deleted) tagging Prime Minister Narendra Modi: “PresVu is the first DCGI-approved proprietary prescription eye drops to ...

(Bloomberg) -- Bausch Health Cos. is working with Jefferies Financial Group to explore refinancing some of its debt to aid a long-planned spinoff of its stake in the eye-care company Bausch + Lomb ...

Company operates a contact lens manufacturing facility in Waterford where approximately 1,500 people are employed.

Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don’t think like your typical corporate board, ...